LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Hemagglutination Assay Kit Diagnoses and Monitors Treatment of Syphilis

By LabMedica International staff writers
Posted on 12 Jul 2011
Image:  ASI TPHA kit (photo courtesy of Arlington Scientific).
Image: ASI TPHA kit (photo courtesy of Arlington Scientific).
A fast, reliable hemagglutination assay aids in detecting, diagnosing, and monitoring the treatment of syphilis.

The Treponema pallidum hemagglutination assay (TPHA) test is a qualitative and semiquantitative hemagglutination test for the presence of immunoglobulin G (IgG) and IgM antibodies to Treponema pallidum, the causative agent of syphilis in human serum and ethylenediaminetetraacetic acid (EDTA) plasma. Serum is the sample of choice and any repeat or confirmatory testing must be done with serum.

The syphilis testing kit, a product of Arlington Scientific, Inc. (ASI; Springville, Utah, USA) contains 100 tests per vial and includes liquid controls. It does not need reconstitution and has up to 18-month shelf life (from date of manufacture). Two levels of controls are included: reactive, and nonreactive.

Blood tests for syphilis are divided into nontreponemal and treponemal tests. Nontreponemal tests are used initially and include venereal disease research laboratory (VDRL) and rapid plasma reagin (RPR). Positive results are often confirmed with a treponemal test such as TPHA or fluorescent treponemal antibody absorption test (FTA-Abs). ASI manufactures RPR, TPHA, and VDRL test kits and the ASiManager-AT, a digital agglutination card reader.

Related Links:

Arlington Scientific Inc.



New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
8-Channel Pipette
SAPPHIRE 20–300 µL
Hemodynamic System Monitor
OptoMonitor

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more